Back to dashboard
All PlansAdministrativeMedium impact

08.01.90d, Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™)

Independence Blue Cross·Pharmacy
Effective date
Not stated
We identified it
Jul 2, 2026
Days to comply

Summary

Failed to analyze policy change

Action Required

Action needed
Manual review required
08.01.90d, Amivantamab-vmjw (Rybrevant®) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro™) | Independence Blue Cross | PolicyChanges.app